Home / Research library / Thymosin Beta-4
Thymosin Beta-4: molecular data, studies & sources
Thymosin Beta-4 is catalogued here as a research compound. This profile brings together the molecular source record, selected indexed publications and available supplier comparisons. Evidence for a named substance does not authenticate a commercial product.
Compiled by PeptideTech Editors · Sources checked · Selected bibliography, not a systematic review
Molecular formula, weight & structure
- Molecular formula (MF)
- C212H350N56O78S
- Molecular weight (MW)
- 4963 g/mol
- PubChem compound ID
- 45382195
- Record title
- Thymosin Beta 4
Values describe the selected PubChem molecular entity. Counterions, salt forms, hydration and sequence changes can alter the supplied material. Confirm the exact identity against the supplier specification.
Source: PubChem CID 45382195 · retrieved 2026-09-21
Chemical identifiers and source data
- IUPAC name
- 4-[[2-[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[1-[2-[[1-[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[2-[[2-[[2-[[1-[2-[[2-[(2-acetamido-3-hydroxypropanoyl)amino]-3-carboxypropanoyl]amino]-6-aminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-carboxypropanoyl]amino]-4-methylsulfanylbutanoyl]amino]propanoylamino]-4-carboxybutanoyl]amino]-3-methylpentanoyl]amino]-4-carboxybutanoyl]amino]-6-aminohexanoyl]amino]-3-phenylpropanoyl]amino]-3-carboxypropanoyl]amino]-6-aminohexanoyl]amino]-3-hydroxypropanoyl]amino]-6-aminohexanoyl]amino]-4-methylpentanoyl]amino]-6-aminohexanoyl]amino]-6-aminohexanoyl]amino]-3-hydroxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-hydroxybutanoyl]amino]-5-amino-5-oxopentanoyl]amino]-4-carboxybutanoyl]amino]-6-aminohexanoyl]amino]-4-amino-4-oxobutanoyl]pyrrolidine-2-carbonyl]amino]-4-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-6-aminohexanoyl]amino]-4-carboxybutanoyl]amino]-3-hydroxybutanoyl]amino]-3-methylpentanoyl]amino]-4-carboxybutanoyl]amino]-5-amino-5-oxopentanoyl]amino]-4-carboxybutanoyl]amino]-6-aminohexanoyl]amino]-5-amino-5-oxopentanoyl]amino]propanoylamino]acetyl]amino]-5-[(1-carboxy-2-hydroxyethyl)amino]-5-oxopentanoic acid
- InChIKey
- UGPMCIBIHRSCBV-UHFFFAOYSA-N
- SMILES
- CCC(C)C(C(=O)NC(CCC(=O)O)C(=O)NC(CCCCN)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(CC(=O)O)C(=O)NC(CCCCN)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(C(C)O)C(=O)NC(CCC(=O)O)C(=O)NC(C(C)O)C(=O)NC(CCC(=O)N)C(=O)NC(CCC(=O)O)C(=O)NC(CCCCN)C(=O)NC(CC(=O)N)C(=O)N2CCCC2C(=O)NC(CC(C)C)C(=O)N3CCCC3C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CCC(=O)O)C(=O)NC(C(C)O)C(=O)NC(C(C)CC)C(=O)NC(CCC(=O)O)C(=O)NC(CCC(=O)N)C(=O)NC(CCC(=O)O)C(=O)NC(CCCCN)C(=O)NC(CCC(=O)N)C(=O)NC(C)C(=O)NCC(=O)NC(CCC(=O)O)C(=O)NC(CO)C(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CCSC)NC(=O)C(CC(=O)O)NC(=O)C4CCCN4C(=O)C(CCCCN)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C
Identifiers
- PubChem CID
- 45382195
- InChIKey
- UGPMCIBIHRSCBV-UHFFFAOYSA-N
Calculated molecular descriptors
| Monoisotopic (exact) mass | 4960.4863 Da |
|---|---|
| Heavy atoms | 347 |
| Hydrogen-bond donors | 72 |
| Hydrogen-bond acceptors | 76 |
| Rotatable bonds | 180 |
| Topological polar surface area | 2220.7 Ų |
| Calculated logP (Crippen) | -25.41 |
| Rings | 4 |
| Stereocenters | 47 |
| Formal charge | 0 |
Computed with RDKit from the published SMILES (Crippen logP, topological polar surface area). Calculated descriptors are not measured properties of a supplied batch.
Registered clinical trials
Studies registered on ClinicalTrials.gov that list Thymosin Beta-4 as an intervention. Studies that only measure the molecule as a biomarker, or use it only as a comparator or background arm for another drug, are excluded. A registration describes a planned or completed protocol; it does not report a result. Active studies are listed first.
9 registered studies matched, 1 currently active or recruiting, 6 with results posted on ClinicalTrials.gov.
- By highest phase
- Phase 2 · 8Phase 1 · 1
- By registry status
- Completed · 4Terminated · 2Withdrawn · 2Not Yet Recruiting · 1
| Study | Phase · status | Conditions | Sponsor · size |
|---|---|---|---|
| Recombinant Human Thymosin Beta 4 for Injection(NL005) for Acute Myocardial InfarctionNCT07586865 · start 2026-05-18 · primary completion 2027-08-17 | Phase 2Not Yet Recruiting | Acute Myocardial Infarction (AMI) · Acute Myocardial Infarction of Anterior Wall · Acute Myocardial Infarction With ST Elevation · Acute Myocardial Infarction of Left Ventricle · Acute Myocardial Infarction With ST Segment Elevation | Beijing Northland Biotech. Co., Ltd.189 participants |
| A Study of the Safety and Efficacy of Injectable Thymosin Beta 4 for Treating Acute Myocardial InfarctionNCT01311518 · start 2019-07 · primary completion 2020-07 | Phase 2WithdrawnWhy stopped: Trial never initiated | Acute Myocardial Infarction · ST Elevation Myocardial Infarction · STEMI | RegeneRx Biopharmaceuticals, Inc.Enrollment not listed |
| Safety and Efficacy of Thymosin Beta 4 Ophthalmic Solution in Patients With Dry EyeNCT01387347 · start 2011-08 · primary completion 2011-10 | Phase 2CompletedResults posted 2012-12-24 | Dry Eye Syndrome · Dry Eye | ReGenTree, LLC72 participants |
| Comparative Study of Thymosin Beta 4 Eye Drops vs. Vehicle in the Treatment of Severe Dry EyeNCT01393132 · start 2011-03 · primary completion 2012-12 | Phase 2CompletedResults posted 2015-12-23 | Dry Eye · Sjogren's Syndrome · Graft vs. Host Disease | Michigan Cornea Consultants, PC9 participants |
| A Phase 1 Safety Study of the Intravenous Administration of Thymosin Beta in Healthy VolunteersNCT00743769 · start 2008-04 · primary completion 2017-01-01 | Phase 1WithdrawnWhy stopped: Study never initiated due to contract manufacturing issues | Myocardial Infarction · Myocardial Ischemia | RegeneRx Biopharmaceuticals, Inc.Enrollment not listed |
| A Phase 2 Study of the Safety and Efficacy of Thymosin Beta 4 for Treating Corneal WoundsNCT00598871 · start 2007-12 · primary completion 2009-02 | Phase 2TerminatedResults posted 2010-04-13Why stopped: slow recruitment | Diabetes | ReGenTree, LLC12 participants |
| Study of Thymosin Beta 4 in Patients With Venous Stasis UlcersNCT00832091 · start 2006-07 · primary completion 2009-01 | Phase 2CompletedResults posted 2010-03-24 | Venous Stasis Ulcers | RegeneRx Biopharmaceuticals, Inc.72 participants |
| Study of Thymosin Beta 4 in Patients With Pressure UlcersNCT00382174 · start 2006-05 · primary completion 2008-12 | Phase 2CompletedResults posted 2010-02-01 | Pressure Ulcers | RegeneRx Biopharmaceuticals, Inc.72 participants |
| A Phase 2 Study on Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis BullosaNCT00311766 · start 2006-02 · primary completion 2010-07 | Phase 2TerminatedResults posted 2013-06-10Why stopped: Lack of patient availability and expiration of study drug | Epidermolysis Bullosa | RegeneRx Biopharmaceuticals, Inc.30 participants |
Registry check 2026-10-09 · Run this search on ClinicalTrials.gov
Human intervention studies
Selected studies in which participants received Thymosin Beta-4, with their indexed or reviewed study type. Check the original article for the formulation, population and controls. Studies that only measured the molecule, or used it as a comparator, are listed separately below and are not counted as intervention studies.
- Human study · PubMed trial index Compound given to participants
Thymosin beta-4 and venous ulcers: clinical remarks on a European prospective, randomized study on safety, tolerability, and enhancement on healing.
Guarnera G, DE Rosa A, Camerini R et al. · Annals of the New York Academy of Sciences · 2007
PMID 17495250 · DOI: 10.1196/annals.1415.003
Preclinical research, reviews & other publications
Animal studies, laboratory experiments, reviews and other indexed papers answer different questions. A review is secondary evidence; a case report does not estimate how often an outcome occurs.
- Preclinical / laboratory research
Chemical characterization of thymosin beta 4.
Low TL, Goldstein AL · The Journal of biological chemistry · 1982
PMID 7054160
- Research publication · design requires review
Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model.
Sosne G, Ousler GW · Clinical ophthalmology (Auckland, N.Z.) · 2015
PMID 26056426 · DOI: 10.2147/OPTH.S80954
- Review · secondary evidence
Cardioprotection by Thymosin Beta 4.
Pipes GT, Yang J · Vitamins and hormones · 2016
PMID 27450736 · DOI: 10.1016/bs.vh.2016.04.004
Thymosin Beta-4 supplier sources
Scientific sources describe molecules and experiments. The commercial links below identify recorded supplier packages. A publication or chemical database entry does not verify the seller, purity, sterility or contents of a lot. Some links are affiliate links; see our disclosure.
Thymosin Beta-4 for sale: compare prices, sizes and forms from every tracked supplier →
| Supplier | Recorded packages | Example source listing |
|---|---|---|
| Amino USAUSD | 10mg Vial · 5mg Vial2 recorded offers | 10mg Vial · $80.00Checked Nov 6, 2026Supplier listing, Thymosin Beta-4 10mg Vial, Amino USA, opens in a new tab |
| Cenexa LabsUSD | 10mg Vial1 recorded offers | 10mg Vial · $149.99Checked Nov 6, 2026Supplier listing, Thymosin Beta-4 10mg Vial, Cenexa Labs, opens in a new tab |
Reference sources & further reading
- PubChem compound record 45382195 — chemical identity and structure.
The citations above link directly to publication records. Encyclopedia links are background reading and are not used to establish clinical effectiveness.
Search for additional research
These links run searches; their results have not been individually reviewed and can include unrelated compounds.
Research information is not a dosing guide or a recommendation for personal use. Study findings are specific to the formulation, population and methods tested. Read our source and correction policy.
Related research profiles
AOD-9604
C78H123N23O23S2
1815.1 g/mol · PubChem CID 71300630
2 selected publications · 0 human intervention studies
ARA-290
C51H84N16O21
1257.3 g/mol · PubChem CID 91810664
7 selected publications · 3 human intervention studies · 2 registered trials
Protein / peptide · highest stage: Phase 2
BPC-157
C62H98N16O22
1419.5 g/mol · PubChem CID 9941957
7 selected publications · 1 human intervention study · 3 registered trials
Protein / peptide · highest stage: Phase 1
KPV
C16H30N4O4
342.43 g/mol · PubChem CID 125672
8 selected publications · 0 human intervention studies
LL-37
C205H340N60O53
4493 g/mol · PubChem CID 16198951
4 selected publications · 0 human intervention studies · 2 registered trials
PTD-DBM
Molecular identity needs further verification
3 selected publications · 0 human intervention studies